Therapeutic Efficacy and Safety of Methotrexate in Moderate-to-Severe Atopic Dermatitis: A Retrospective Study of Korean Patients at Tertiary Referral Hospital
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Methotrexate (MTX) has been prescribed to suppress atopic dermatitis (AD) symptoms and flares in moderate- to-severe cases. Objective: The purpose of this study was to evaluate the therapeutic efficacy and safety of MTX as well as the suppressive activity of MTX to reduce flares in moderate-to-severe AD patients. Methods: Patients with moderate-to-severe AD who were treated with MTX at the Chonnam National University Hospital were retrospectively studied. Results: Total 102 patients (79 males, 23 females) with a median age of 22.0±10.3 years were studied. The median initial dose of MTX was 10.3±2.6 mg/week, and the MTX-weekly dose was increased by 2.5 to 5 mg at an interval of 2 to 4 weeks to a maximum dose of 17.5±2.7 mg/week. The median maintenance dose was 11.7±2.1 mg/week; the median duration of treatment with MTX was 34.0±38.8 weeks. The initial response was noted after 5.8±3.7 weeks. Of the 102 patients, 60.8% (62/102) showed successful treatment response and 39.2% (40/102) showed mild or no improvement. MTX therapy effectively suppressed the frequency of AD flares by more than 50% in 71.1% (32/45) of the patients who responded among the MTX responders group. The most common adverse events were transient liver abnormality (5.9%, 6/102) and gastrointestinal discomfort (3.9%, 4/102), but no serious adverse events occurred. Conclusion: Our results reveal that MTX is a relatively safe drug to control moderate-to-severe AD with satisfactory therapeutic efficacy and inhibitory activity against AD flares.
Abstract
Background: Methotrexate (MTX) has been prescribed to suppress atopic dermatitis (AD) symptoms and flares in moderate- to-severe cases. Objective: The purpose of this study was to evaluate the therapeutic efficacy and safety of MTX as well as the suppressive activity of MTX to reduce flares in moderate-to-severe AD patients. Methods: Patients with moderate-to-severe AD who were treated with MTX at the Chonnam National University Hospital were retrospectively studied. Results: Total 102 patients (79 males, 23 females) with a median age of 22.0±10.3 years were studied. The median initial dose of MTX was 10.3±2.6 mg/week, and the MTX-weekly dose was increased by 2.5 to 5 mg at an interval of 2 to 4 weeks to a maximum dose of 17.5±2.7 mg/week. The median maintenance dose was 11.7±2.1 mg/week; the median duration of treatment with MTX was 34.0±38.8 weeks. The initial response was noted after 5.8±3.7 weeks. Of the 102 patients, 60.8% (62/102) showed successful treatment response and 39.2% (40/102) showed mild or no improvement. MTX therapy effectively suppressed the frequency of AD flares by more than 50% in 71.1% (32/45) of the patients who responded among the MTX responders group. The most common adverse events were transient liver abnormality (5.9%, 6/102) and gastrointestinal discomfort (3.9%, 4/102), but no serious adverse events occurred. Conclusion: Our results reveal that MTX is a relatively safe drug to control moderate-to-severe AD with satisfactory therapeutic efficacy and inhibitory activity against AD flares.
참고문헌 (20)
- Hernández-Martín A, "Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients", J Eur Acad Dermatol Venereol, 31, pp.837~842 (2017)
- Hijnen DJ, "Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis", J Eur Acad Dermatol Venereol, 21, pp.85~89 (2007)
- Sibbald C, "Retrospective review of relapse after systemic cyclosporine in children with atopic dermatitis", Pediatr Dermatol, 32, pp.36~40 (2015)
- Sarıcaoğlu H, "Cyclosporine-A for severe childhood atopic dermatitis : clinical experience on efficacy and safety profile", Turk J Med Sci, 48, pp.933~938 (2018)
- Goujon C, "Methotrexate for the treatment of adult atopic dermatitis", Eur J Dermatol, 16, pp.155~158 (2006)
- Deo M, "Methotrexate for treatment of atopic dermatitis in children and adolescents", Int J Dermatol, 53, pp.1037~1041 (2014)
- Warren RB, "British Association of Dermatologists’guidelines for the safe and effective prescribing of methotrexate for skin disease 2016", Br J Dermatol, 175, pp.23~44 (2016)
- Dvorakova V, "Methotrexate for severe childhood atopic dermatitis : clinical experience in a tertiary center", Pediatr Dermatol, 34, pp.528~534 (2017)
- Goujon C, "Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis : a phase III randomized noninferiority trial", J Allergy Clin Immunol Pract, 6, pp.562~569.e3 (2018)
- Chan ES, "Molecular action of methotrexate in inflammatory diseases", Arthritis Res, 4, pp.266~273 (2002)
- Thomas S, "Methotrexate is a JAK", STAT pathway inhibitor, 2015, pp.10, e0130078~
- Weatherhead SC, "An open-label, dose-ranging study of methotrexate for moderateto-severe adult atopic eczema", Br J Dermatol, 156, pp.346~351 (2007)
- Purvis D, "Longterm effect of methotrexate for childhood atopic dermatitis", J Paediatr Child Health, 55, pp.1487~1491 (2019)
- Taieb Y, "The use of methotrexate for treating childhood atopic dermatitis : a multicenter retrospective study", J Dermatolog Treat, 30, pp.240~244 (2019)
- Knöpfel N, "Methotrexate for severe nummular eczema in children : Efficacy and tolerability in a retrospective study of 28 patients", Pediatr Dermatol, 35, pp.611~615 (2018)
- Langan SM, "What is meant by a"flare"in atopic dermatitis? A systematic review and proposal", Arch Dermatol, 142, pp.1190~1196 (2006)
- Thomas KS, "Validation of treatment escalation as a definition of atopic eczema flares", PLoS One, 10, pp.e0124770~ (2015)
- Leroux JL, "Effects of methotrexate on leukotriene and derivated lipoxygenase synthesis in polynuclear neutrophils in rheumatoid polyarthritis", Rev Rhum Mal Osteoartic, 59, pp.587~591 (1992)
- Montaudié H, "Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity", J Eur Acad Dermatol Venereol, 25(Suppl 2), pp.12~18 (2011)
- Irvine AD, "A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe atopic eczema trial (TREAT)", Br J Dermatol, 179, pp.1297~1306 (2018)